奥美拉唑与兰索拉唑治疗慢性胃炎、胃溃疡患者的疗效及对血清PCT、GAS水平的影响

doi:10.3969/j.issn.1671-7171.2022.04.024

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1159 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨奥美拉唑与兰索拉唑治疗慢性胃炎、胃溃疡患者的疗效及对血清降钙素原(PCT)及胃泌素(GAS)水平的影响。【方法】选取2019年2月至2021年2月三原县医院收治的72例慢性胃炎胃溃疡患者,根据随机数字表法将其分为观察组和对照组,每组36例。对照组采用奥美拉唑治疗,观察组给予兰索拉唑治疗,两组治疗时间均为14 d。比较两组患者症状消失时间,临床疗效,血清PCT、GAS水平,幽门螺杆菌(Hp)根除率以及不良反应发生情况。【结果】观察组患者反酸、嗳气、上腹痛、腹胀症状消失时间均短于对照组,差异有统计学意义(P<0.05)。观察组患者临床总有效率为94.44%(34/36),显著高于对照组的75.00%(27/36),差异有统计学意义(P<0.05)。治疗前,两组患者血清PCT、GAS水平比较,差异无统计学意义(P>0.05);治疗后,两组患者血清PCT、GAS水平均低于治疗前,且观察组低于对照组(P<0.05)。观察组患者Hp根除率为94.44%(34/36),高于对照组的77.78%(28/36),差异有统计学意义(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。【结论】兰索拉唑用于治疗慢性胃炎、胃溃疡患者能够缩短临床症状消失时间,疗效较好,同时能够降低血清PCT、GAS水平,提高Hp根除率,安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘颖
	高菂

关键词 ：胃炎/药物疗法, 胃溃疡/药物疗法, 奥美拉唑/治疗应用, 兰索拉唑/治疗应用, 降钙素/血液

Abstract：【Objective】To investigate the efficacy of omeprazole and lansoprazole in the treatment of chronic gastritis and gastric ulcer and their effects on the levels of serum procalcitonin (PCT) and gastrin (gas). 【Methods】 A total of 72 patients with chronic gastritis and gastric ulcer treated in our hospital from February 2019 to February 2021 were randomly divided into observation group and control group, with 36 cases in each group. The control group was treated with omeprazole and the observation group was treated with lansoprazole. The treatment time of both groups was 14 days. The symptom disappearance time, clinical efficacy, serum PCT and gas levels, HP eradication rate and adverse reactions were compared between the two groups.【Results】The disappearance time of acid reflux, belching, epigastric pain and abdominal distension in the observation group was shorter than that in the control group (P<0.05).The total clinical effective rate in the observation group was 94.44% (34/36), which was significantly higher than 75.00% (27/36) in the control group (P<0.05); Before treatment, there was no significant difference in the levels of serum PCT and GAS between the two groups (P>0.05); After treatment, the levels of serum PCT and GAS in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The eradication rate of HP in the observation group was 94.44% (34/36), which was higher than 77.78% (28/36) in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Lansoprazole in the treatment of patients with chronic gastritis and gastric ulcer can shorten the disappearance time of clinical symptoms and has good curative effect. At the same time, it can reduce the levels of serum PCT and gas and improve the eradication rate of HP. It is safe and reliable.

Key words： Gastritis/DT Stomach Ulcer/DT Omeprazole/TU Lansoprazole/TU Calcitonin/BL

收稿日期: 2021-11-12

中图分类号:

R573.3

通讯作者: *E-mail:hxgd520@163.com

引用本文:

刘颖, 高菂. 奥美拉唑与兰索拉唑治疗慢性胃炎、胃溃疡患者的疗效及对血清PCT、GAS水平的影响[J]. 医学临床研究, 2022, 39(4): 565-567.
LIU Ying, GAO Di. Efficacy of Omeprazole and Lansoprazole in the Treatment of Chronic Gastritis and Gastric Ulcer and their Effects on Serum PCT and GAS Levels. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 565-567.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.04.024 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I4/565

[1] CHERVINETS V M, MIRONOV A Y, CHERVINETS Y V, et al. The state and role of esophagus, stomach, intestinal microbiota in patients with ulcer disease, chronic gastritis, esophagitis[J].Klin Lab Diagn,2020, 65(1):42-49.
[2] RAHMAN M O, ISLAM A S, CHOUDHURY M S, et al. A study of association between H.pylori genotype and chronic gastritis[J].Mymensingh Med J,2020, 29(3):664-675.
[3] JAVED S, SKOOG E C, SOLNICK J V. Impact of helicobacter pylori virulence factors on the host immune response and gastric pathology[J].Curr Top Microbiol Immunol,2019, 21(7):21-52.
[4] 王准, 龚天斌. 奥美拉唑联合多潘立酮在胃溃疡患者中的临床效果分析[J].现代消化及介入诊疗, 2019, 24(8):921-923.
[5] CHO Y K, CHOI M G, CHOI S C, et al. Randomised clinical trial:tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer[J].Aliment Pharmacol Ther,2020, 52(5):789-797.
[6] SHAMSDIN S A, ALBORZI A, GHADERI A, et al. Significance of TC9 and TH9 in Helicobacter pylori-induced gastritis[J].Helicobacter,2020, 25(1):1267-1275.[7] 李华珊, 高峰, 张杰. 胃黄色瘤及幽门螺杆菌核酸联合分型检测与胃良性疾病严重程度之间的关系[J].中国医刊, 2019, 54(10):1075-1078.
[8] 李彬龙, 和水祥, 李颜霞. 两种方案根除消化性溃疡和慢性胃炎患者幽门螺杆菌的疗效对比[J].西部医学, 2019, 31(7):1053-1056.
[9] 李莉芳. 奥美拉唑联合雷尼替丁对胃溃疡黏膜表皮生长因子,血管内皮生长因子及溃疡愈合质量的影响[J].实用临床医药杂志, 2018, 22(22):17-20.
[10] WEI B, WANG Y, WU H, et al. Pharmacodynamics and Pharmacokinetics of a New Type of Compound Lansoprazole Capsule in Gastric Ulcer Rats and Beagle Dogs:Importance of Adjusting Oxidative Stress and Inflammation[J].Pharmaceutics,2019, 11(2):49-56.
[11] 刘宏伟, 黄玉洁, 杨剑英, 等. 铝碳酸镁、兰索拉唑、阿莫西林、呋喃唑酮四联疗法治疗幽门螺杆菌相关性胃溃疡的效果及安全性评价[J].中国综合临床, 2020, 36(1):22-27.
[12] ABED M N, ALASSAF F A, JASIM M H M, et al. Comparison of antioxidant effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole[J].Pharmacology,2020, 105(11-12):645-651.
[13] 李鑫. 铝碳酸镁联合兰索拉唑与单用兰索拉唑治疗幽门螺杆菌相关性胃溃疡的疗效对比[J].现代消化及介入诊疗, 2018, 23(2):178-180.